Compare NUCL & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUCL | TTRX |
|---|---|---|
| Founded | 2023 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.2M | 298.8M |
| IPO Year | 2026 | 2025 |
| Metric | NUCL | TTRX |
|---|---|---|
| Price | $6.05 | $11.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 213.9K | 131.9K |
| Earning Date | 10-20-2026 | 11-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $900.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.63 | $2.57 |
| 52 Week High | $14.22 | $16.45 |
| Indicator | NUCL | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 37.90 | 43.50 |
| Support Level | $5.75 | $9.02 |
| Resistance Level | $6.45 | $14.39 |
| Average True Range (ATR) | 0.31 | 1.44 |
| MACD | 0.01 | -0.42 |
| Stochastic Oscillator | 27.50 | 1.44 |
Eagle Nuclear Energy Corp is a next-generation nuclear energy company that seeks to combine domestic uranium exploration and development with proprietary small modular reactor (SMR) technology. It holds the rights to the mineable, measured and indicated uranium deposit in the United States, referred to as the Aurora Uranium Project, located in southeastern Oregon. The Aurora Uranium Project includes the Aurora deposit, with an estimated 37.73 million pounds of near-surface uranium and the adjacent Cordex Zone Eagle's SMR technology. Eagle's mission is to supply uranium to the growing nuclear energy industry and play a role in the global transition to clean, reliable, and affordable energy.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.